Cenobamate tablets as a treatment for focal-onset seizures in adults

References

• Steinhoff BJ. Anticonvulsant drug therapy of adolescents and adults. State of the art. Z eitschrift für Epileptologie. 2013;26(3):142–153.
   Google Scholar
• Steinhoff BJ. The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience. Ther Adv Neurol Disord. 2015;8(3):137–147.
   PubMed Web of Science ®Google Scholar
• Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991 Jun;41(6):889–926.
   PubMed Web of Science ®Google Scholar
• Shinnar S. Tiagabine. Semin Pediatr Neurol. 1997 Mar;4(1):24–33.
   PubMedGoogle Scholar
• Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy. 2001 Aug;21(8):904–919.
   PubMed Web of Science ®Google Scholar
• Galiana GL, Gauthier AC, Mattson RH. Eslicarbazepine acetate: a new improvement on a classic drug family for the treatment of partial-onset seizures. Drugs R D. 2017 Sep;17(3):329–339.
   PubMed Web of Science ®Google Scholar
• Hamandi K, Sander JW. Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure. 2006 Mar;15(2):73–78. Epub 2006 Jan 18.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Staack AM. Levetiracetam and brivaracetam. A review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord. 2019 Sep 9;12:1756286419873518.
   Web of Science ®Google Scholar
• Steinhoff BJ, Staack AM, Hillenbrand BC. Randomized controlled antiepileptic drug trials miss almost all PWE with ongoing seizures. Epilepsy Behav. 2017;66:45–48. Epub 2016 Dec 26.
   PubMed Web of Science ®Google Scholar
• Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs. A 30 year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286.
   PubMed Web of Science ®Google Scholar
• French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Oct 29;388(10056):2153–2163. Epub 2016 Sep 6.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Cannabidiol in dravet syndrome study group. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017 May 25;376(21):2011–2020.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Cross JH, et al. GWPCARE3 study group. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. 2018 May 17;378(20):1888–1897.
   PubMed Web of Science ®Google Scholar
• Lagae L, Sullivan J, Knupp K, et al. FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019 Dec 21;394(10216):2243–2254. Epub 2019 Dec 17.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Mistry A, Zuberi S, et al. FAiRE, DS study group. Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020 Mar 1;77(3):300–308.
   PubMed Web of Science ®Google Scholar
• Martínez-Lizana E, Gil-Lopez F, Donaire A, et al. Outcome of treatment changes in patients with drug-resistant chronic epilepsy: a tertiary center experience. Epilepsy Res. 2017;136:97–102. Epub 2017 Jul.
   PubMed Web of Science ®Google Scholar
• Park KM, Kim SE, Lee BI. Antiepileptic drug therapy in patients with drug-resistant epilepsy. J Epilepsy Res. 2019 30;9(1):14–26. e Collection 2019 Jun.
   PubMedGoogle Scholar
• Krauss GL, Klein P, Brandt C, et al. Safety and Efficacy of Adjunctive Cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38–48. Epub 2019 Nov 14.
   PubMed Web of Science ®Google Scholar
• Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020 Jun 2;94(22):e2311–e2322.
   PubMed Web of Science ®Google Scholar
• Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020 Jun;61(6):1099–1108. Epub 2020 May 12
   PubMed Web of Science ®Google Scholar
• Keam SJ. Cenobamate: first approval. Drugs. 2020;80(1):73–78.
   PubMed Web of Science ®Google Scholar
• Vernillet L, Greene SA, Kamin M. Pharmacokinetics of cenobamate: results from single and multiple oral ascending-dose studies in healthy subjects. Clin Pharmacol Drug Dev. 2020 May 9;9(4):428–443. Epub 2020 Feb 22.
   PubMed Web of Science ®Google Scholar
• Xcopri Prescribing Information. 21 November 2019; 03.10.2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf
   Google Scholar
• Lattanzi S, Trinka E, Zaccara G, et al. Adjunctive cenobamate for focal-onset seizures in adults: a systematic review and meta-analysis. CNS Drugs. 2020 Nov;34(11):1105–1120.
   PubMed Web of Science ®Google Scholar
• Wheless JW. Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review. Expert Rev Neurother. 2020 Nov;20(11):1085–1098. Epub 2020 Nov 4.
   PubMed Web of Science ®Google Scholar
• Vossler DG. Remarkably high efficacy of cenobamate in adults with focal-onset seizures: a double-blind, randomized, placebo-controlled trial. Epilepsy Curr. 2020 24;20(2):85–87. eCollection 2020 Mar-Apr.
   PubMed Web of Science ®Google Scholar
• Sperling MR, Greenspan A, Cramer JA, et al. Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials. Epub 2009 Oct 27 Epilepsia. 2010;513:333–343.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ. Cenobamate -. A new perspective for epilepsy treatment. Nervenarzt. 2020 Sep 29. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Guignet M, Campbell A, White HS. Cenobamate (XCOPRI): can preclinical and clinical evidence provide insight in its mechanism of action? Epilepsia. 2020;61(11):2329–2339.
   PubMed Web of Science ®Google Scholar
• Klein P, Krauss GL, Aboumatar S, et al.. Long-term efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study [Abstract]. Annual Meeting of the American Epilepsy Society;2019;Baltimore, Maryland, 6. – 10. 12.2019,Abstract 2.206.
   Google Scholar
• Sharma R, Nakamura M, Neupane C, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020 Jul 15;879:173117. Epub 2020 Apr 20.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Sho JH, Shin H, et al. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175–182. Epub 2019 May 4.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the Fifteenth EilatConference on New Antiepileptic Drugs and Devices (EILAT XV). II. drugs in more advanced clinical development. Epilepsia. 2020 Nov;61(11):2365–2385. Epub 2020 Nov 9.
   PubMed Web of Science ®Google Scholar
• Vernillet L, Kamin M Pharmacokinetics of cenobamate (YKP3089): results from single and multiple oral rising-dose studies in healthy subjects [Abstract no. P5.280]. Neurology 2018;91(Suppl 15): 90no.P5.280].
   Google Scholar
• Vernillet L, Kamin M. Drug-drug interactions between cenobamate and other antiepileptic drugs: results from phase I studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium [Abstract]. Clin Pharmacol Ther. 2018;103(Suppl S1):S91.
   Google Scholar
• Binnie C. Proof of principle trials: EEG surrogate endpoints. Epilepsy Res. 2001;45(1–3):7–11.
   PubMed Web of Science ®Google Scholar
• Binnie CD, DGA K-NT, De Korte R. Photosensitivity as a model for acute antiepileptic drug studies. Electroencephalogr Clin Neurophysiol. 1986;63(1):35–41.
   PubMedGoogle Scholar
• Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenité D, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia. 1986;27(3):248–254.
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenité DGA. Reflex seizures induced by intermittent light stimulation. In: Zifkin BG, Andermann F, Beaumanoir A, et al., editors. Reflex epilepsies and reflex seizures. advances in neurology, bd. 75. Philadelphia: Lippincott-Raven Press; 1998. S. p. 99–121.
   Google Scholar
• Kasteleijn-Nolst Trenité DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69(10):1027–1034.
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenité DG, Groenwold RHH, Schmidt B, et al. Single dose efficacy evaluation of two partial benzodiazepine receptor agonists in photosensitive epilepsy patients: a placebo-controlled pilot study. Epilepsy Res. 2016;122:30–36.
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenité DG, Parain D, Genton P, et al. Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprosilant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model. Epilepsy Behav. 2013;28(1):66–70.
   PubMed Web of Science ®Google Scholar
• Trenitè DG, French JA, Hirsch E, et al. Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study. Epilepsy Res. 2007;74(2–3):193–200.
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenité DGA, DiVentura BD, Pollard JR, et al. Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089). Neurology. 2019;93(6):e559–e567. Epub 2019 Jul 10.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Sánchez-Àlvarez JC, Majkowska-Zwolinska B, et al. Efficacy and safety of cenobamate as adjunctive therapy in patients with uncontrolled focal seizures: results from two double-blind, placebo-controlled, international studies. Presented at 6th Congress of the European Academy of Neurology. Eur J Neurol. 2020;27(Suppl 1): 60. May 23rd – May 26th, 2020.
   Google Scholar
• French JA, Chung SS, Krauss GL, et al.. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study [Abstract]. Annual Meeting of the American Epilepsy Society;2019;Baltimore, Maryland, 6. – 10. 12.2019,Abstract 3.297.
   Google Scholar
• Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314(7075):180–181.
   PubMed Web of Science ®Google Scholar
• Leppik IE. Felbamate. Epilepsia. 1995;36(Suppl 2):S66–72.
   PubMed Web of Science ®Google Scholar
• Splinter MY. Efficacy of Retigabine in Adjunctive Treatment of Partial Onset Seizures in Adults. J Cent Nerv Syst Dis. 2013;5:31–41.
   PubMedGoogle Scholar
• Arnold S. Cenobamate: new hope for treatment-resistant epilepsy. Epub 2019 Nov 14 Lancet Neurol. 2020;191:23–24.
   PubMed Web of Science ®Google Scholar
• Costa J, Fareleira F, Ascencao R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epub 2011 Apr 19 Epilepsia. 2011;527:1280–1291.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epub 2013 May 10 Epilepsia. 2013;548:1481–1489.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Mameniskiene R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Epub 2016 Jun 22 Neurology. 2016;873:314–323.
   PubMed Web of Science ®Google Scholar
• Steinhoff BJ, Fröscher W. Importance of therapeutic drug monitoring of anticonvulsants. An overview. Z Epileptol. 2011;24(1):6–11.
   Google Scholar
• Kamin M, Rosenfeld WE, Ferrari L. Safety of cenobamate for the treatment of focal seizures, following 1-wwek versus 2-week titration schedules [Abstract]. Annual Meeting of the American Epilepsy Society;2019;Baltimore, Maryland, 6.-10.12.2019, Abstract 3.295.
   Google Scholar
• Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or valproate: a record linkage study. Neurology. 1997;49(2):542–546.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epub 2007 Mar 26 Epilepsia. 2007;487:1223–1244.
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovanelli F, Giorgi FS, et al. Tolerability of new antiepileptic drugs: a network meta-analysis. Eur J Clin Pharmacol. 2017;73(7):811–817.
   PubMed Web of Science ®Google Scholar
• Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of lamotrigine-associated rash. Epilepsia. 2006;47(2):318–322.
   PubMed Web of Science ®Google Scholar
• Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017 Jun 29;6(6):CD011412.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee H, Kim DW. Switching antiepileptic drugs to once-daily dosing regimens in epilepsy patients. Acta Neurol Scand. 2020 Aug 6. Online ahead of print.
   Web of Science ®Google Scholar